Table 7. Human primary mesothelioma cell lines exposed to 3d and reference antitumor drugs.
| Cpd | EPITHELIOID | BIPHASIC | SARCOMATOID | ||||||
|---|---|---|---|---|---|---|---|---|---|
| IC50 ± SD (μM) | |||||||||
| MM288 | MM317 | MM404 | MM473 | MM481 | MM487 | MM491 | MM432 | MM472 | |
| 3d | 0.48±0.1 | 0.85±0.2 | 1.4 ±0.3 | 2.1±0.5 | 11.7±1.2 | 0.2±0.05 | 0.87±0.3 | 0.16±0.03 | 0.048±0.01 |
| Irinotecan | 14.9±2.0 | 7.0 ± 1.0 | 9.4 ± 0.7 | 10.0±2.0 | |||||
| SAHA | 3.8 ±0.2 | 11.2±0.9 | 8.8± 1.2 | 8.5± 0.4 | 11.5±0.4 | 7.4 ± 0.4 | 10.7±0.4 | 6.9 ± 1.0 | 4.6 ± 0.8 |
| Gefitinib | 38.7±1.4 | 26.1±2.9 | 28.4±2.4 | 18.4±0.7 | 31.2±1.0 | 15.0±0.5 | 14.0±0.7 | 17.1 ± 1.0 | 19.1 ± 0.5 |
| Cisplatin | 8.1 ± 0.3 | 4.2 ± 0.6 | 2.4 ± 0.5 | 2.4 ± 0.2 | 7.0 ± 1.5 | 3.0 ± 0.5 | 6.5 ± 0.9 | 5.0 ± 0.8 | 1.26 ± 0.1 |
| 5-FU | >200(35%) | 17.9±3.1 | 52.2±8.7 | 35.2±8.4 | 27.4±2.2 | >200(48%) | 44.0±10.3 | >200(34%) | 40. ± 10.5 |
Human primary mesothelioma cells were exposed to 3d and different anti-tumor compounds. Anti-proliferative activity was assessed upon 72 h with the SBR assay.